DomaniCell, LLC is a wholly-owned subsidiary of Progenitor Cell Therapy, LLC (www.progenitorcelltherapy.com). Founded in 1997 by medical and scientific leaders in the cell therapy field, privately-held Progenitor Cell Therapy, also known as PCT, has become the leading provider of cell therapy support services to its client companies worldwide from its state-of-the-art clean room facilities and laboratories in the United States. PCT has performed over 15,000 cell-based procedures since its operations began. An ever-increasing roster of cell therapy companies and leading stem cell transplantation programs rely on PCT.

Headquartered in New Jersey, PCT and its subsidiary, DomaniCell, is a profitable and stable company on solid financial footing. Each parent choosing DomaniCell to collect and store their baby’s cord blood stem cells can share in the same confidence as expressed in PCT by its institutional investors and some of the world’s foremost cell therapy companies which entrust the development of their products to PCT.

As a member of the Progenitor Cell Therapy group of companies, DomaniCell is uniquely positioned to leverage internal scientific, manufacturing, and clinical expertise to benefit its partners and clientele. A partnership with DomaniCell also ensures that the physicians and patients in partner hospitals remain up-to-date on the research and clinical advances in cord blood and cellular therapy.

Click here to learn more about Progenitor Cell Therapy.